volume 100 issue 1 pages 27-37

NSG mice as hosts for oncological precision medicine

Claudia Maletzki 1, 2
Stephanie Bock 3, 4, 5
Philipp Fruh 3, 4, 5
Karolis Macius 3, 4, 5
Anika Witt 3, 4, 5
Friedrich Prall 6
Friedrich Prall 7
Michael Linnebacher 3
Michael Linnebacher 4, 5
1
 
Department of Medicine, Clinic III-Hematology/Oncology/Palliative Care Rostock, Rostock, Germany
2
 
Department of Medicine, Clinic III-Hematology/Oncology/Palliative Care Rostock, Rostock, Germany.
3
 
Molecular Oncology and Immunotherapy; Department of General Surgery, Rostock, Germany
4
 
Molecular Oncology and Immunotherapy
5
 
Department of General Surgery, Rostock, Germany.
Publication typeJournal Article
Publication date2020-01-01
scimago Q1
wos Q1
SJR1.254
CiteScore8.5
Impact factor4.2
ISSN00236837, 15300307
Molecular Biology
Cell Biology
Pathology and Forensic Medicine
Abstract
Patient-derived xenograft (PDX) models have been rediscovered as meaningful research tool. By using severely immunodeficient mice, high-engraftment rates can be theoretically achieved, permitting clinical stratification strategies. Apart from engraftment efficacy, tolerability towards certain cytostatic drugs varies among individual mouse strains thus impeding large-scale screenings. Here, we aimed at optimizing an in vivo treatment schedule using the widely applied cytostatic drug 5-fluoruracil (5-FU) for exemplary response prediction in colorectal cancer (CRC) PDX models. Four different individual CRC PDX models were engrafted into NOD.Cg-PrkdcscidIl2rgtm1Wjl (NSG) mice. Mice with established PDX were allocated to different treatment groups, receiving 5-FU, the oral prodrug Capecitabine, or 5-FU/leucovorin (LV) at different doses. Body weight, tumor size, and general behavior were assessed during therapy. Ex vivo analyses were done from blood samples, liver, as well as tumor resection specimen. Engraftment efficacy was high as expected in NSG mice, yielding stable PDX growth for therapy stratification. However, overall tolerability towards 5-FU was unexpectedly low, whereas the prodrug Capecitabine as well as the combination of 5-FU/LV at low doses were well tolerated. Accompanying plasma level determination of DYPD, the rate-limiting enzyme for 5-FU-mediated toxicity, revealed reduced activity in NSG mice compared with other common laboratory mouse strains, offering a likely explanation for the drug incompatibility. Also, the De Ritis quotient was highly elevated in treated mice, reflecting overall organ injury even at low doses. Summarizing these findings, NSG mice are ideal hosts for in vivo engraftment studies. However, the complex immunodeficiency reduces tolerance to certain drugs, thus making those mice especially sensitive. Consequently, such dose finding and tolerance tests constitute a necessity for similar cancer precision medicine approaches. The severe immunodeficiency of NOD.Cg-PrkdcscidIl2rgtm1Wjl (NSG) mice, a widely used strain for generating patient-derived xenografts from primary tumors, impairs drug metabolism and reduces tolerability towards common cytostatic drugs. Consequently, dose finding and tolerance tests are strongly recommended prior to perform large-scale cancer precision medicine approaches.
Found 
Found 

Top-30

Journals

1
2
3
Cancers
3 publications, 7.89%
PLoS ONE
3 publications, 7.89%
Laboratory Animals
2 publications, 5.26%
Translational Oncology
2 publications, 5.26%
Nature Cancer
1 publication, 2.63%
DMM Disease Models and Mechanisms
1 publication, 2.63%
Future Microbiology
1 publication, 2.63%
Pharmaceutical patent analyst
1 publication, 2.63%
Diagnostics
1 publication, 2.63%
Frontiers in Immunology
1 publication, 2.63%
Journal of Experimental and Clinical Cancer Research
1 publication, 2.63%
iScience
1 publication, 2.63%
Seminars in Cancer Biology
1 publication, 2.63%
Trends in Cancer
1 publication, 2.63%
Cancer Research
1 publication, 2.63%
Blood advances
1 publication, 2.63%
Toxicology and Applied Pharmacology
1 publication, 2.63%
International Journal of Molecular Sciences
1 publication, 2.63%
Frontiers in Oncology
1 publication, 2.63%
Molecular Therapy Oncology
1 publication, 2.63%
Human Cell
1 publication, 2.63%
Chemical Engineering Journal
1 publication, 2.63%
Laboratory Animal Research
1 publication, 2.63%
Expert Opinion on Drug Discovery
1 publication, 2.63%
Apoptosis : an international journal on programmed cell death
1 publication, 2.63%
BMC Cancer
1 publication, 2.63%
npj Breast Cancer
1 publication, 2.63%
World Journal of Gastroenterology
1 publication, 2.63%
1
2
3

Publishers

1
2
3
4
5
6
7
Springer Nature
7 publications, 18.42%
Elsevier
6 publications, 15.79%
MDPI
5 publications, 13.16%
Taylor & Francis
3 publications, 7.89%
Public Library of Science (PLoS)
3 publications, 7.89%
Cold Spring Harbor Laboratory
3 publications, 7.89%
SAGE
2 publications, 5.26%
Frontiers Media S.A.
2 publications, 5.26%
Neoplasia Press
2 publications, 5.26%
The Company of Biologists
1 publication, 2.63%
American Association for Cancer Research (AACR)
1 publication, 2.63%
American Society of Hematology
1 publication, 2.63%
Baishideng Publishing Group
1 publication, 2.63%
1
2
3
4
5
6
7
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
38
Share
Cite this
GOST |
Cite this
GOST Copy
Maletzki C. et al. NSG mice as hosts for oncological precision medicine // Laboratory Investigation. 2020. Vol. 100. No. 1. pp. 27-37.
GOST all authors (up to 50) Copy
Maletzki C., Bock S., Fruh P., Macius K., Witt A., Prall F., Prall F., Linnebacher M., Linnebacher M. NSG mice as hosts for oncological precision medicine // Laboratory Investigation. 2020. Vol. 100. No. 1. pp. 27-37.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41374-019-0298-6
UR - https://doi.org/10.1038/s41374-019-0298-6
TI - NSG mice as hosts for oncological precision medicine
T2 - Laboratory Investigation
AU - Maletzki, Claudia
AU - Bock, Stephanie
AU - Fruh, Philipp
AU - Macius, Karolis
AU - Witt, Anika
AU - Prall, Friedrich
AU - Prall, Friedrich
AU - Linnebacher, Michael
AU - Linnebacher, Michael
PY - 2020
DA - 2020/01/01
PB - Springer Nature
SP - 27-37
IS - 1
VL - 100
PMID - 31409886
SN - 0023-6837
SN - 1530-0307
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Maletzki,
author = {Claudia Maletzki and Stephanie Bock and Philipp Fruh and Karolis Macius and Anika Witt and Friedrich Prall and Friedrich Prall and Michael Linnebacher and Michael Linnebacher},
title = {NSG mice as hosts for oncological precision medicine},
journal = {Laboratory Investigation},
year = {2020},
volume = {100},
publisher = {Springer Nature},
month = {jan},
url = {https://doi.org/10.1038/s41374-019-0298-6},
number = {1},
pages = {27--37},
doi = {10.1038/s41374-019-0298-6}
}
MLA
Cite this
MLA Copy
Maletzki, Claudia, et al. “NSG mice as hosts for oncological precision medicine.” Laboratory Investigation, vol. 100, no. 1, Jan. 2020, pp. 27-37. https://doi.org/10.1038/s41374-019-0298-6.